AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.100
-0.070 (-3.23%)
Aug 7, 2025, 4:00 PM - Market closed
The Shyft Group Revenue
AC Immune had revenue of 1.31M CHF in the quarter ending June 30, 2025, with 90.10% growth. This brings the company's revenue in the last twelve months to 28.92M, up 86.71% year-over-year. In the year 2024, AC Immune had annual revenue of 27.31M with 84.51% growth.
Revenue (ttm)
28.92M CHF
Revenue Growth
+86.71%
P/S Ratio
5.74
Revenue / Employee
168,128 CHF
Employees
172
Market Cap
205.80M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.31M | 12.51M | 84.51% |
Dec 31, 2023 | 14.80M | 10.87M | 276.14% |
Dec 31, 2022 | 3.94M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 15.43M | -95.03M | -86.03% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Novo Nordisk | 49.11B |
Eli Lilly and Company | 49.00B |
ACIU News
- 3 days ago - AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 months ago - AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - GlobeNewsWire
- 4 months ago - AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewsWire
- 5 months ago - AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 9 months ago - AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
- 1 year ago - AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 - GlobeNewsWire
- 1 year ago - AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward - Seeking Alpha